News for Genmab A/S (GE9.F)

Vancouver, British Columbia, March 01, 2021 (GLOBE NEWSWIRE) -- The global immunotherapy drugs market is projected to reach value of USD 365.57 Billion by ...

Innovating Antibodies, Improving Lives Investor Presentation March 2021 ? Genmab Forward... | March 1, 2021

The following slide deck was published by Genmab A/S in conjunction with their 2020 Q4 earnings call.

Genmab A/S (NASDAQ:GMAB) Q4 2020 Earnings Conference Call February 23, 2021, 12:00 ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO...

Company Announcement Repurchase of up to 200,000 shares Mitigating dilution from warrant exercises and honoring commitments under our Restricted

Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020,...

ADC Therapeutics SA ADCT, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and

Genmab A/S gets positive recommendation for marketing approval for its subcutaneous ofatumumab for the treatment of relapsing forms of multiple sclerosis in adults with active...

RARITAN, N.J., Jan. 28, 2021 /PRNewswire/ --  The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS